Stock Ratings / Health Care / CNSP / financials

ENVB (37) IMRN (58) FBLG (40) UPC (33) ⌘ Pro Terminal →

CNS Pharmaceuticals Inc. (CNSP) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$4.77 +5.77% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.81

CNS Pharmaceuticals Inc. (CNSP) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $7.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.81 (+0.85%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-4.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CNSP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (48/100 Composite)

🔍 WHY CNSP SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (31% of score)

FRED Regime × Technicals: 33% of 52W Range • RSI-14 at 48.9 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$5.35-9.3% Next Q

Q2 (-2Q)

Grade C-$4.85+2.5% Next Q

Q3 (-1Q)

Grade C-$4.97-4% Next Q

Current

Grade D$4.77-5.6% Hist 90D α

Trajectory: C (56) → D (48)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CNSP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CNSP currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.33) and Max Pain ($5.01) forces dealer call-delta covering toward $11.07.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CNSP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CNSP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 48%NO 52%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CNSP Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.4%	-$16.0K	-$13.8M	-45%
FY 2024	$4.00B	52%	-0.4%	-$14.9K	-$17.1M	-45%
FY 2023	$4.00B	52%	-0.5%	-$18.9K	-$14.1M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CNSP)

✓Walkthrough of CNSP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CNSP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +110.13%⚡ TESTING RESISTANCE

2026-10-30O $4.60H $5.01L $4.25C $4.77VOL 52.9K

RES: $5.40SUP: $3.58SMA50: $5.33SMA200: $4.59

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CNSP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CNSP Butterfly Map → + Track CNSP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CNSP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CNSP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CNSP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CNSP)

Health Care Rank #397 of 1016 ⚔️ ENVB vs CNSP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CNSP vs. ENVB, IMRN, FBLG, UPC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CNS Pharmaceuticals Inc. (CNSP) ranks #397 by composite RQD confidence (48/100, grade D) and #921 by equity capitalization ($7.0M). Within this direct 5-issuer industry benchmark cohort, CNSP leads on earnings valuation at N/A trailing P/E, while CNSP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IMRN currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with CNSP at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CNSP ACTIVE CNS Pharmaceuticals Inc.	D	48/100	—	—	-35.0%	+5.77%	$7.0M	Benchmark Subject
ENVB Enveric Biosciences Inc.	D-	37/100	—	—	-35.0%	-0.68%	$6.5M	/envb-vs-cnsp →
IMRN Immuron Limited	D+	58/100	—	—	—	+2.48%	$7.4M	/imrn-vs-cnsp →
FBLG FibroBiologics Inc.	D-	40/100	—	—	-35.0%	-3.99%	$6.3M	/fblg-vs-cnsp →
UPC Universe Pharmaceuticals Inc. (Class A)	E	33/100	—	35.3%	—	-20.21%	$7.7M	/upc-vs-cnsp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001729427

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CNS Pharmaceuticals Inc. (CNSP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$16.0K, operating cash flow of -$13.8M, and free cash flow of -$13.8M (+19.2% YoY). On the balance sheet, CNSP closed FY2025 with $8.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$16.0K	-$13.8M	-$13.8M	$8.6M	—
FY2024 (FY)	2024-12-31	$0	-$14.9K	-$17.1M	-$17.1M	$8.7M	—
FY2023 (FY)	2023-12-31	$0	-$18.9K	-$14.1M	-$14.1M	—	—

3. CNSP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CNSP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $4.77 (+5.77% 1D, market cap $7.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CNSP ranks #397 in composite RQD confidence.

How does CNSP compare to ENVB and IMRN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CNSP carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ENVB (Enveric Biosciences Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $6.5M) and IMRN (Immuron Limited) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $7.4M). Among the 5-stock peer group, CNSP leads on earnings multiple (N/A) while CNSP leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CNSP?

Per CNSP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001729427), CNS Pharmaceuticals Inc. generated $0 in revenue, -$16.0K in net income, and -$13.8M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CNSP trading relative to its 50-day, 200-day, and 52-week technical levels?

CNSP last traded at $4.77 (+5.77% on volume of 46,398 shares), positioning the stock -10.51% below its 50-day simple moving average ($5.33) and +3.92% above its 200-day simple moving average ($4.59). Across its 52-week range of $1.90 to $10.54, CNSP sits at the 33.2% percentile with a 14-day RSI of 48.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.17 to $5.37).

CNSP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is CNS Pharmaceuticals Inc. (CNSP)?

In FY 2025 (10-K), CNSP converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: CNSP RQD Cockpit CNSP 12M Forecast CNSP Earnings & Move CNSP Dividends & DRIP CNSP Insiders & 13F CNSP Whale Options CNSP Profit Sankey CNSP News & Why